NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Clinical Trials (1)
Korean Post-marketing Surveillance for Xeljanz XR
Started Jan 2022
200 enrolled
Active Moderate to Severe Rheumatoid ArthritisActive Ankylosing SpondylitisActive Psoriatic Arthritis
Loss of Exclusivity
LOE Date
Sep 14, 2034
103 months away
Patent Expiry
Sep 14, 2034
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| RE41783 | Dec 8, 2025Expired | Substance | — |
| RE41783*PED | Jun 8, 2026 | — | |
| 10639309 | Mar 14, 2034 | Product | — |
| 9937181 | Mar 14, 2034 | Product | — |
| 11253523 | Mar 14, 2034 | U-3329 |